D-Day For CHRS, ENDO Pained, FDA Lifts Clinical Hold On INO's VGX-3100 Trial

Today's Daily Dose brings you news about FDA's decision on Endo's marketed opioid pain medication; Adamas' updated analysis of phase III trial results of ADS-5102 for the treatment of levodopa-induced dyskinesia in people with Parkinson's disease and BioTime's clinical trial catalyst to watch out for.

from RTT - Biotech http://ift.tt/2s9KwjD
via IFTTT